Development and application of a prognostic model based on radiomics and artificial intelligence for patients with lung adenocarcinoma brain metastasis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Creation and utilization of a prognostic framework incorporating radiomics and artificial intelligence for lung adenocarcinoma patients with brain metastases

  • By

  • Congying Zheng

  • Xinyuan Yang

  • Musen Ye

  • Kai Tang

  • Shubin Wang

  • June 30, 2026

Share

  • 1

    The study developed a prognostic model integrating radiomics and clinical factors for lung adenocarcinoma patients with brain metastases.

  • 2

    A cohort of 176 patients was divided into training and test sets to evaluate the model's performance using logistic regression and AUC.

  • 3

    Independent prognostic factors identified included EGFR mutation status, number of brain metastases, and Lung-molGPA score.

  • 4

    The radiomics model achieved AUCs of 0.862 in the training set and 0.829 in the test set, indicating strong diagnostic performance.

  • 5

    The combined nomogram demonstrated superior predictive performance with AUC values of 0.904 and 0.874 in the training and test sets, respectively.

Original Source(s)

Development and application of a prognostic model based on radiomics and artificial intelligence for patients with lung adenocarcinoma brain metastasis

  • by Congying Zheng, Xinyuan Yang, Musen Ye, Kai Tang, Shubin Wang

  • June 30, 2026

Related Content

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • by

  • August 26, 2026

  • 5 min